Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

Stephen A. Bustin, Vladimı́r Beneš, Jeremy A. Garson et al. · Clinical Chemistry · 2009 · 16.1K citations · Full text

Pharmacy, Molecular Biology, Analytical Chemistry +12

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2015 · 605 citations

Medicine, Hematology, Immunology +14

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Françoise Huguet, Delphine Réa et al. · Blood · 2006 · 530 citations

Pharmacy, Hematology, Pharmacotherapy +3